

The 5th SABPA Pacific Forum 2009

Steve A. Bent, J.D. | Partner, Foley & Lardner LLP



Stephen A. Bent, a Partner with Foley & Lardner LLP, is the founder and a former co-chair of the firm's Life Sciences Industry Team. As a principal in the firm's China initiative, he also is active in Foley & Lardner's Shanghai office.

The Practical Law Company's Cross Border Life Sciences Handbook has ranked Mr. Bent as one of the top five U.S. life sciences attorneys in the IP category annually since 2004. Since 2007, he also has been selected annually by his peers for inclusion in The Best Lawyers in America® for the area of biotechnology law.

Mr. Bent counsels clients on intellectual property disputes and the legal issues associated with pharmaceutical and biotechnology asset valuation and management, venture capital, licensing and technology transfer, and corporate acquisitions.

A graduate of Earlham College (B.S., biology), the University of Connecticut (M.S., 1976), and the George Washington University Law School (J.D., with high honors, 1981), Mr. Bent served as technical assistant to the Honorable Phillip B. Baldwin, Circuit Judge, U.S. Court of Appeals for the Federal Circuit, from 1981 to 1983. He is a member of the editorial board of The Scientist.

Hui Cai, PhD, MBA, | VP, Business Development, WUXI AppTec; Chair of the Board, SABPA



Dr. Hui Cai is Vice President of Business Development at WUXI AppTec, a 4000-employee integrated pharmaceutical R&D service company traded on New York Stock Exchange (NYSE: WX). She brought to WX with a broad portfolio of expertise in strategic planning, business development, and portfolio management as President of Inflexion BioPartners and Vice President of Corporate Development at HUYA Bioscience. Prior to that, Dr. Cai spent ten years at Johnson & Johnson Pharmaceutical Research and Development, co-leading multiple small molecule drug discovery programs. She is a co-author and co-inventor to over 40 scientific publications and issued or pending patents.

Dr. Cai was appointed by the Mayor of San Diego, in 2002, and has served as a Commissioner at City of San Diego Science and Technology Commission. She is Chairwoman of SABPA, and Chair of the San Diego section of the American Chemical Society.

Dr. Cai received her BS and MS in Chemistry from Peking University, PhD from The Scripps Research Institute, and MBA from UCSD Rady School of Management as a recipient of the distinguished DLA Piper - Athena FlexMBA Scholarship.

Chun-Lin Chen, Ph.D. | CEO, Medicilon



Dr. Chunlin Chen is the CEO and co-founder of Medicilon, one of the leading CROs for pharmaceutical R&D in China. Medicilon provides integrated services including biology, structure biology, chemistry and preclinical services to pharmaceutical and biotech companies worldwide. In 2008, Medicilon formed joint venture with MPI Research for GLP tox services along with other animal testing services. The new 50,000 square feet animal facility has achieved full AAALAC accreditation and offers US IND filing package with the help from MPI.

Dr. Chen got his Ph.D. in 1994 in Pharmacology and Toxicology from Oklahoma State University and did postdoctoral training at St. Jude Children's Research Hospital. During 1997-2002, Dr. Chen served as Director of Pharmaceutical Department at Parker Hughes Cancer Center, Parker Hughes Institute. In 2002, Dr. Chen joined Vertex as a Staff Investigator, then group leader of PKDM, where he managed pre-clinical drug evaluation team and lead to three IND filings approved by FDA.

Dr. Chen has over 80 publications in the field of drug discovery and development. Dr. Chen currently serves as Associate Director for Drug Metabolism Section of Shanghai Pharmacology Society and he received several awards from State and Shanghai as Excellent Returnee.

Peng Chen, Ph.D., J.D. | Partner, Morrison Foerster



Dr. Chen's practice focuses on patent prosecution, client counseling, opinion and litigation and encompasses all fields of the biotechnology and pharmaceutical industries. Dr. Chen has extensive experience in preparing and prosecuting biotechnology and pharmaceutical patents. He has managed entire patent portfolios for biotechnology clients, advising on maximizing clients' patent positions and designing strategy in dealing with other entities' patents. Dr. Chen also has been litigating biotechnology patents, especially in the area of in vitro diagnostics.

Dr. Chen was selected by his peers for inclusion in the 2009 and 2010 editions of The Best Lawyers in America in Biotechnology Law and Intellectual Property Law. He was also ranked in the 2008 and 2009 editions of Legal 500 United States® as a leading lawyer in patent licensing.

Partial List of Representative Matters:

- On behalf of one client, obtained U.S. patent protection for a novel diagnostic test, advised in designing around a third party's patents, and worked with a Morrison & Foerster team to win a case of patent dispute.
- Invalidated the asserted claims of Abbott's 484 patent through reexamination.
- Convinced the U.S. Patent Office to allow broad claims for an application that had been prosecuted for 10 years.

Xiangming Fang, M.D., Ph.D. | President of SABPA SD, Sr. VP and CSO, eBioCenter Corporation




Dr. Fang is Co-Founder, Senior Vice President and Chief Scientific Officer at eBioCenter Corporation (www.ebiocenter.com), an internet-based company providing marketing and information services in the fields of biopharma and life sciences.

Dr. Fang has 26 years of experience in biomedical research and product development, including 16 years of biotech industry experience and 10 years of management experience. She has strong scientific background with integrated knowledge in medicine, molecular and cell biology, protein chemistry and immunology. Previously as the Senior Vice President and Chief Scientific Officer at GenWay Biotech, she is responsible for new technology and product development and production, as well as customer support and partnership coordination. Prior to GenWay, Dr. Fang served at GenStar Therapeutics, initially as the Director of the Cancer Program and the Director of Preclinical Studies, then as Vice President, Hemophilia and Vector Development.

Dr. Fang obtained her M.D. degree from Zhejiang University Medical School and Ph.D. in Molecular Biology from the University of Alabama. She completed her postdoctoral studies at the University of Texas, MD Anderson Cancer Center.

Dr. Xiangming Fang is the current President of SABPA, San Diego chapter. She has served as BOD of SABPA for 6 years.

Ming Guo, Ph.D. | Chairman, Ascentage Pharma; SABPA Board Member



Dr. Ming Guo is a co-founder of Ascentage Pharma, a newly spin-off NCE drug R&D company from Ascenta (Shanghai) R&D Center (a wholly owned subsidiary of Ascenta Therapeutics). Dr. Guo had played a pivotal role in establishment of Ascenta (Shanghai) R&D Center in summer 2005 as one of the first global NCE R&D organizations in China, and assumed its General Manager role for the past 2 years. Dr. Guo has also been Vice President of Pharmaceutical Sciences & Manufacturing at Ascenta since March 2005, working on several NCE programs targeting apoptosis pathways as cancer therapy, as well as on corporate management and business development.

Before Ascenta, Dr. Guo worked at Pfizer for 9 years, leading many aspects of drug development activities, both in-house and outsourced, with technical leadership as well as project management (a project team award recipient at beginning of 2005). Before Pfizer, Dr. Guo worked at Monsanto and ABC Laboratories for 6 years.

Dr. Guo taught at the UCSD Extension about NCE drug development for 2002-2004 and is currently an adjunct faculty at Peking University, China. As a co-founder, Dr. Guo was the first Chairman of the Board and later serves as a Director of SABPA (www.sabpa.org).

Yun He, Ph.D. | Vice President, Research, BioDuro



Yun He, Ph.D., is currently the Vice President of Research at Bioduro (Beijing) Co. Ltd. He was the Head of Medicinal Chemistry at Roche R&D Center in China (RRDCC) from 2006-2008, and a member of RRDCC Senior Management Team and Roche Global Chemistry Leadership Team. Dr. He was an Associate Director of Medicinal Chemistry at the Genomics Institute of the Novartis Research Foundation (GNF) from 2002 to 2006. From 2000 to 2002, he served as a Group Leader in anti-infective research at ISIS Pharmaceuticals. Prior to ISIS, he worked for Abbott Laboratories for four years in the neuroscience field.

Dr. He received his Ph.D. degree in synthetic organic chemistry from the Scripps Research Institute, MS degrees from Lanzhou University and Iowa State University, and BS from Southwest University. He has published over 90 research papers, patents and patent applications.

Dr. He has contributed to the discovery of a number of clinical compounds over the years. He was the president and a board member of the Sino-American Biotechnology and Pharmaceutical Professionals Association (www.SABPA.org), San Diego from 2005 to 2006, and is an editor of *Journal of Chinese Pharmaceutical Sciences*.

Jing-Shan (Jennifer) Hu, Ph.D. | Director, Licensing and External Research, Merck



Jing-Shan Hu was trained in biochemistry and molecular biology at the University of Texas and MD Anderson Cancer Center, where she earned her PhD. After postdoctoral research at Harvard Medical School and Massachusetts General Hospital, Jing-Shan started her biotech career at Human Genome Sciences as a scientist, and later project leader of VEGF-2 Protein Therapeutics Program. She then joined Affymetrix, where she worked in various capacities, including establishing and managing programs with both pharmaceutical and academic partners to demonstrate the application of Affymetrix GeneChip technology in toxicology/pharmacogenomics studies. Prior to joining Merck, Jing-Shan spent 3 years at Roche Pharmaceuticals in Palo Alto, as research leader, head of the Functional Biology group, applying and developing new technologies toward assessment of drug targets and new compounds.

Jing-Shan received her bachelor's degree from Peking University. She has authored 15 papers in peer-reviewed journals including *Science* and *Nature*. She is also an inventor with 16 patents and patent applications.

At Merck, Jing-Shan is responsible for identifying and evaluating new product and technology opportunities in mainland China, Hong Kong, and Taiwan for in-licensing, acquisitions, co-development, alliances, and basic research collaborations. She brings extensive technical expertise, professional experience, and an entrepreneurial spirit to this position.

Charles Q. Huang | Vice President, Business Development, Sundia MediTech Company, Ltd., Shanghai, China



Charles Huang joined Sundia (www.sundia.com) in March 2008, a top Chinese CRO that provides fully-integrated drug discovery and development services to its worldwide clients. First as director of business development (BD), Charles was recently promoted to Vice President of BD. His contact: ghuang888@gmail.com

Prior to Sundia, Charles served as president of Amnova, a pharmaceutical consultant firm in US. He worked for 15 year as medicinal chemist at Neurocrine Bioscience Inc (NBI), Johnson & Johnson and Amylin, including 4-year part-time experience on CRO project management and new market BD for advanced clinic candidate. During his tenure at NBI, Charles made significant contributions to CRF1, CRF-BP, and Insomnia projects, all resulting major collaborations with Johnson and Johnson, Eli Lilly and Pfizer. He is co-author for 20 publications, 10 presentations and 12 US patents.

Charles graduated with BS in Polymer Chemistry from University of Science and Technology of China (USTC) in 1989, and obtained his MS in organic chemistry at California State University at Northridge. Besides his science and business career in drug discovery, Charles founded a non-profit 501c3 charitable organization in 2004 where he served as President (2004-2008) and currently as Chair of Board (2008-2010).

Jeffery Lange, MBA | VP, Business Development, SciClone Pharmaceuticals, Inc.



Jeffery Lange has served as Vice President, Business Development since August 2008. Mr. Lange served most recently as Director, Business Development & Licensing Finance at Novartis in East Hanover, NJ where he was responsible for licensing, divestiture, co-marketing, and merger and acquisition valuation as part of a global negotiation team for Novartis Pharma General Medicines. Prior to that, Mr. Lange held various positions within Novartis including the Head of Strategic Financial Planning in Novartis' Pharma General Medicine group in Basel, Switzerland, and Manager of Business Development and Planning at Novartis Agribusiness. Earlier in his career, he held a variety of positions in planning and analysis, finance and accounting. Mr. Lange earned an M.B.A. with a specialization in Finance from the University of Chicago and a B.B.A. in Accounting from the University of Iowa.

Hui Li, Ph.D. | Senior Principal Scientist, Pfizer Global R&D; SABPA Vice Chairman & Board Member



Dr. Hui Li is currently a senior principal scientist and research project leader at Pfizer Global Research & Development, La Jolla Laboratories. His research interests include structure-based drug design, discovery and development of novel therapeutics in the field of anti-viral, diabetes and ophthalmology. He has worked on the Hepatitis C virus (HCV) program, leading and contributing to the identification and optimization of inhibitors of HCV RNA dependant RNA polymerase, an important target for the development of novel anti-HCV therapeutics.

Dr. Li obtained his B.S degree from Peking University and Ph.D in organic chemistry from University of California, San Diego. There he worked under the guidance of Professor K. C. Nicolaou on new synthetic technology development and the total synthesis of glycopeptide antibiotic Vancomycin. Dr. Li is a founding member of the Sino-American Biomedical & Pharmaceutical Association (SABPA) and is currently serving as vice chairman of the board.

Yuwen Liu, MSc Pharm., MBA | CEO, Suzhou BioBay



Liu Yuwen graduated from China Pharmaceutical University with an MS in Pharmaceutics and MBA at Fudan University, China and Norwegian Management School, and is a licensed pharmacist.

She started her career with Capsugel®, a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to QA manager 1998. In April 2000, she transferred to New Business Development department managing new product market opportunity exploration in great China region. In May 2003, she moved to Shanghai as General Manager to set up representative office for Perrigo (the world's largest manufacturer of OTC pharmaceutical and nutritional products for store brand market) and is taking charge of all related market development activities including JV's in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc.

In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech R&D in China. She became CEO of BioBay and VP of Suzhou Ventures Group, assistance director of Suzhou Industrial Park Science & Technology Bureau 2007.

Minglong Ma | Secretary, Suzhou Industrial Park Working Committee; Standing Member, Suzhou Municipal Committee



Born on 14 November 1965, Mr. Ma Minglong got his master degree in Testing Technology from Southeast University Graduate School in 1989 in Nanjing. He worked for Suzhou Electronics Holding Co. from 1989 to 1998 as senior engineer, chief engineer, assistant GM of Sujing Group, deputy Head of Suzhou Electronic Computer Factory, GM assistant, deputy GM and party member. From March 1998 to July 2000, Mr. Ma was appointed as the deputy secretary of Suzhou Municipal Government and promoted to be the director of Suzhou Municipal Government Science & Technology Committee. Later on, Mr. Ma was appointed as the Mayor of Wujiang City (under Suzhou Municipality) and the chairman of Wuajing ETDZ. Mr. Ma worked for Suzhou Industrial Park from September 2004 as the chairman and promoted to be the party secretary of Suzhou Industrial Park working committee and also the standing member of Suzhou Municipal Committee from April 2008.

Joseph D. Panetta | President and CEO, BIOCUM




As President and CEO of BIOCUM since 1999, Mr. Panetta has been responsible for leading BIOCUM's efforts to position the regional life science community to achieve global success. Working with BIOCUM's staff and Board of Directors, he leads programs in capital formation, public policy, workforce education, and member services. He also oversees several BIOCUM subsidiaries, including a Purchasing Group which provides over \$20 million in products and services to members, and is a co-founder of the BIOCUM Political Action Committee and the California Biotechnology Foundation, of which he is Chairman.

Mr. Panetta is active on various boards, business coalitions and committees addressing issues pertinent to the life science industry, including the San Diego Workforce Partnership, San Diego Regional Economic Development Corporation, San Diego Regional Chamber of Commerce, CleanTECH San Diego, CONNECT, UCSD, San Diego State University, Cal State University San Marcos, eStudySite, and Genlantis. He is chairing the CropLife America Biotechnology Committee and serving as founding member of the International Biotechnology Forum under the auspices of the Biotechnology Industry Organization.

Mr. Panetta holds a Bachelor of Science degree in biology from LeMoyne College and a Master of Public Health in Industrial and Environmental Health from the University of Pittsburgh.

Mario Pennisi | CEO, Queensland Clinical Trials Network Inc. (QCTN)



Mario has extensive experience managing laboratory medicine services. In the mid 1990s, in affiliation with US and German-based organisations, he established the first Queensland-based 'central laboratory' in order to service international trials in the Asia-Pacific region. He was also a founding member of Queensland's first contract research organisation.

Later, as National Business Development Manager for an Australian multinational pharmaceutical/diagnostics company, he collaborated with numerous international sponsors and service providers to achieve significant clinical trials growth in Australia.

Mario believes that the comprehensive range of high quality services available, together with the relatively untapped potential of numerous investigators and patient populations, provide exciting opportunities for the development of clinical trials in Queensland, and has overseen QCTN's growth to over 70 Queensland-based service providers.

Ted Plafker | Senior Writer, The Economist



Since 1989, American journalist Ted Plafker has worked in Beijing and covered all aspects of the ever-changing China story. Writing for The Economist since 1994, he is currently one of the magazine's two accredited China correspondents. He has previously written about China for the South China Morning Post, Boston Globe, Washington Post, Science Magazine, San Francisco Examiner, International Herald Tribune, and others.

Fluent in Mandarin, Plafker has covered China's business, trade and economic affairs; internal politics; security and international relations; and its shifting social and cultural landscape.

His 2007 book, "Doing Business in China: How to Profit in the World's Fastest Growing Market," (Hachette Book Group) offers concise and practical guidance to China's unique business environment. It covers China's complex legal and economic landscape, business ethics, business culture, consumer culture, information environment, expatriate life in China, and more. Its simple aim is to help readers understand what is going on in China today, and learn how they and their firms can operate there effectively.

A New Jersey native, Plafker graduated with a degree in Russian studies from Wesleyan University in 1986. He continues to live in Beijing together with his wife and three sons.

Ivor Royston, M.D. | Founding Managing Partner, Forward Ventures



Dr. Royston is a founding Managing Partner of Forward Ventures. From 1990-2000, he served as the founding President and CEO of the Sidney Kimmel Cancer Center. From 1978 to 1990, he was on the oncology faculty of the University of California, San Diego. In 1978, Dr. Royston co-founded **Hybritech**, Inc., San Diego's first biotechnology company; and in 1986, he co-founded **IDEC** Corporation, which merged with Biogen to form BiogenIdec.

Dr. Royston has been instrumental in the formation, financing, and development of numerous biotechnology companies, including: Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; Morphotek (acquired by Eisai), Sequana Therapeutics (acquired by Celera); and Triangle Pharmaceuticals (acquired by Gilead).

Dr. Royston's recent portfolio investments include Altair, HemaQuest; LigoCyte (Chairman), Syndax, and TargeGen (Chairman).

Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1994, Dr. Royston received the San Diego Entrepreneur of the Year Award. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. In 2006, Dr. Royston was inducted into the San Diego Entrepreneur Hall of Fame.

Sylvie Sakata, Ph.D. | Senior Director, External Research Solutions, Pfizer



Sylvie received her Bachelor of Science with Honors at the University of California Irvine in 1993. She continued her studies organic chemistry and natural product synthesis with Professor Larry Overman, and obtained her PhD at UCI in 1998.

She started her industrial career at Agouron Pharmaceutical in the Chemical Research and Development as a research scientist and had the opportunity to lead projects within Development. Over a three year period she worked on the development of the Rhino Virus (common cold) and HIV NNRTI programs.

In 2001, she redirected her career to Medicinal Chemistry as a Senior Principal Scientist where she continued to work in many Antiviral programs at Warner Lambert, now Pfizer. During the same period, she led the entire chemistry sourcing strategy for Pfizer La Jolla. As associate Director of Chemistry Sourcing, she led all chemistry services for both Pfizer La Jolla (2006-2008) and Nagoya Research (2006-2007) sites. From mid-2008, she holds the position of Senior Director, leading the External Research Solutions for Pfizer La Jolla in charge of Chemistry, Biology, and DMPK services in the pre-clinical sourcing.

She has experienced in working with Asia/EU/North America sourcing partners, API and Analytical services and integrated sourcing programs.

Zhu Shen, Ph.D., MBA | Pacific Forum Co-chair; CEO, BioForesight; Vice Chairman and Board Member, SABPA



Dr. Zhu Shen is the award-winning CEO of BioForesight, a strategic consulting company providing licensing, investment advisory, and media/public relations services to life science clients across the Pacific. She also held positions at The Wilkerson Group/ IBM, Bayer, Chiron, and Immusol, with increasing responsibilities in business development, strategic planning, and corporate communications.

Dr. Shen is a widely recognized thought leader in US/China business. She is an organizer, speaker, and chair of numerous life science business conferences and has authored articles on cross-Pacific life science trends on Pharmaceutical Executive and Genetic Engineering News. She has been featured on CBS Evening News, Fox News, Business Week, Los Angeles Times, China Economic Review, San Diego Union Tribune, ASIA Media, etc.

Dr. Shen sits on the Editorial Advisory Board of PharmAsia News and is Vice Chairman/ board member of SABPA. She also serves on the BIOCOCOM CalAsia Programming Committee.

Dr. Shen was honored with the Asian Heritage Award, SABPA Achievement Awards, and nominated for the Athena Pinnacle Award and San Diego Business Journal's "Women Who Mean Business Award" multiple times. She received her Ph.D. in Biochemistry from the University of Colorado and MBA from the Johnson School at Cornell University. Further info: www.bioforesight.biz.

Ben Wang, Esq. | Senior Patent Counsel, Celera Corporation



Mr. Wang graduated from Fudan University with a Bachelor's Degree in Biology. He conducted biomedical research in signal transduction and gene regulation for four years as a PhD candidate in Molecular and Cell Biology at Harvard University. Mr. Wang obtained his Master's degree in Biology from Harvard before attending law school at Georgetown University Law Center, graduating with a Juris Doctor degree in 1995.

Mr. Wang is licensed to practice law in California and Washington, DC. He is a registered U.S. patent attorney.

For the past four years, Mr. Wang has been Senior Patent Counsel at Celera Corporation. Before that, he had been in-house counsel for several biotech startups, serving as their chief IP strategist.

During his years in private practice, Mr. Wang worked with Chinese startup companies and research institutions, providing his clients with strategic counseling in patent portfolio development, third party patent analyses, and licensing of IP assets.

Mr. Wang's legal expertise encompasses the following:

- IP due diligence including third-party patent analysis and infringement opinion.
- Patent preparation and prosecution, both U.S. and international.
- Negotiating corporate agreements such as licensing, collaboration, supply, etc.
- High level strategic planning of corporate IP creation and commercialization.

Sean Shao-Hwa Wang, Ph.D. | President, ITRI International Inc. (a subsidiary of ITRI Taiwan)



Sean is President of ITRI International, which is Taiwan Industrial Technology Research Institute's presence in North America. ITRI International engages in incubation, R&D collaboration, training and recruiting, technology transfer, and IP business. Sean joined ITRI in 2004 as General Director of IEK, a business unit of ITRI that conducts market research and business consulting and functions as a government think tank.

Before joining ITRI, for 15 years, Sean was with SRI International/SRI Consulting, where he developed and implemented international proprietary projects on technology evaluation, feasibility study, strategic planning, licensing strategy, new business opportunities identification, and new plant investment decision for international clients, including major energy, material, and chemical companies worldwide. He was also the managing editor of *Process Economics Program Yearbook*, which provides chemical production economics in the U.S., Germany, Japan, and China. Earlier, Sean was associated with M.W. Kellogg and U.S. DOE.

Sean is on the board of advisors of several startups and also involved in several technology and business associations. He is the advisor of TAITA and the general secretary of Monet Jade Science & Technology Associations. He received his BS from National Taiwan University and MS and PhD from West Virginia University, all in chemical engineering.

Ian Wisenberg, SVP | Strategic Development, ChinaBio



Ian Wisenberg has more than 25 years experience in international business with an emphasis in finance, capital formation, business development and administration.

He is founder and managing partner of BioGlobal Consulting Group (BGCG) and currently serves as ChinaBio's Senior Vice President of Strategic Development. Prior to founding BioGlobal Consulting Group, he served as the Senior Vice President of Business Development and CFO of BIOCUM – the world's largest regional life science trade organization.

Bringing a broad portfolio of expertise, Ian has a solid track record in Capital Development initiatives aimed at establishing strategic financial partnerships with local, national and international financing institutions. He was also responsible for the VC incubator in San Diego. Of equal significance is his ability to foster international relations with government agencies and private institutions.

Mr. Wisenberg also serves on the Board of Directors for two local biotech companies and is treasurer for the San Diego Venture Group.

Prior to BIOCUM, he was Vice President of finance and administration, as well as interim President, Secretary and treasurer of Aerocast, Inc., a secured broadband media streaming company.

Mr. Wisenberg holds a Bachelor of Commerce Degree in accounting from Cape Town University and is a Certified Public Accountant.

Shuguang Zhu, Ph.D. | CSO, AstaTech, Inc.; Co-Chair, the 5th SABPA Pacific Forum



Dr. Zhu is the CSO of AstaTech, Inc, a contract research and chemical manufacturing company providing services to pharmaceutical and biotech companies.

Dr. Zhu has 15 years of experience in small molecule drug research and development and API manufacturing, including over 10 years of management experience in biotech industry. Prior to working at AstaTech, Dr.Zhu was the Director of process of chemistry at Ardea Biosciences, Director of process development at Ascenta Therapeutics, and a senior scientist at Chiron Corporation. He has a strong chemical, manufacturing and control (CMC) leadership background and is an expert in process development, chemical outsourcing and GMP API manufacturing. Dr. Zhu was a panelist at ChemOutsourcing 2008 and biotech advisor for ChemOutsourcing 2009.

Dr. Zhu obtained his Ph.D. in Chemistry from Memorial University of Newfoundland and M.Sc. in Chemistry from Sichuan University. He completed his postdoctoral fellowship at the University of Toronto and taught chemistry in Huazhong University of Science & Technology for seven years.

Dr. Shuguang Zhu is the co-chair of the 5th SABPA Pacific Forum.

Xiaoming Zou, Ph.D. | Director, External Drug Discovery, GSK



Xiaoming Zou is currently Director of External Drug Discovery for GSK's Immuno-Inflammation Center of Excellence of Drug Discovery with responsibility in identifying, establishing and managing external partnerships. Prior to GSK, he was a member of Amgen's outreach team as Sr. Manager, Licensing and subsequently Director, External R&D Affairs. He had worked on sourcing, evaluating and executing of licensing deals in inflammation and neuroscience therapeutic areas. Xiaoming was trained as an immunologist and holds Ph.D. from Columbia University and M.S. and B.S. from Tsinghua University.